Vericel (NASDAQ:VCEL – Get Free Report) and Entera Bio (NASDAQ:ENTX – Get Free Report) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings and profitability.
Analyst Ratings
This is a breakdown of recent ratings and price targets for Vericel and Entera Bio, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vericel | 0 | 0 | 7 | 0 | 3.00 |
| Entera Bio | 0 | 0 | 1 | 0 | 3.00 |
Vericel presently has a consensus price target of $51.33, indicating a potential downside of 0.71%. Entera Bio has a consensus price target of $10.00, indicating a potential upside of 474.71%. Given Entera Bio’s higher probable upside, analysts clearly believe Entera Bio is more favorable than Vericel.
Valuation and Earnings
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vericel | $197.52 million | 12.72 | -$3.18 million | ($0.01) | -5,164.84 |
| Entera Bio | $130,000.00 | 478.90 | -$8.89 million | ($0.28) | -6.21 |
Vericel has higher revenue and earnings than Entera Bio. Vericel is trading at a lower price-to-earnings ratio than Entera Bio, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Vericel has a beta of 1.7, meaning that its share price is 70% more volatile than the S&P 500. Comparatively, Entera Bio has a beta of 1.6, meaning that its share price is 60% more volatile than the S&P 500.
Insider & Institutional Ownership
14.1% of Entera Bio shares are held by institutional investors. 5.2% of Vericel shares are held by insiders. Comparatively, 10.9% of Entera Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.
Profitability
This table compares Vericel and Entera Bio’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vericel | 0.22% | 0.21% | 0.13% |
| Entera Bio | N/A | -103.40% | -85.00% |
Summary
Vericel beats Entera Bio on 8 of the 12 factors compared between the two stocks.
About Vericel
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
About Entera Bio
Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures. Its other product candidate is GLP-2, which is in preclinical trial for the treatment of short bowl syndrome; and OXM for the treatment of obesity and metabolic diseases. The company has a research collaboration and license agreement with the Amgen Inc. for the development and discovery of clinical candidates in the field of inflammatory disease and other serious illnesses. Entera Bio Ltd. was incorporated in 2009 and is based in Jerusalem, Israel.
Receive News & Ratings for Vericel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vericel and related companies with MarketBeat.com's FREE daily email newsletter.
